CY1112557T1 - Σχηματισμoi οι οποiοι περιλαμβανουν αντι-κωδικεyσης νουκλεοτιδια σε συνδετινες - Google Patents
Σχηματισμoi οι οποiοι περιλαμβανουν αντι-κωδικεyσης νουκλεοτιδια σε συνδετινεςInfo
- Publication number
- CY1112557T1 CY1112557T1 CY20121100139T CY121100139T CY1112557T1 CY 1112557 T1 CY1112557 T1 CY 1112557T1 CY 20121100139 T CY20121100139 T CY 20121100139T CY 121100139 T CY121100139 T CY 121100139T CY 1112557 T1 CY1112557 T1 CY 1112557T1
- Authority
- CY
- Cyprus
- Prior art keywords
- format
- connections
- includes anti
- coding nucleotides
- ligand
- Prior art date
Links
- 239000002773 nucleotide Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000003828 downregulation Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000016273 neuron death Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000003981 vehicle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ33392899 | 1999-01-27 | ||
| NZ50019099 | 1999-10-07 | ||
| EP05016736A EP1621212B1 (en) | 1999-01-27 | 2000-01-27 | Formulations comprising antisense nucleotides to connexins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112557T1 true CY1112557T1 (el) | 2016-02-10 |
Family
ID=26652011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100139T CY1112557T1 (el) | 1999-01-27 | 2012-02-09 | Σχηματισμoi οι οποiοι περιλαμβανουν αντι-κωδικεyσης νουκλεοτιδια σε συνδετινες |
| CY20141100703T CY1115521T1 (el) | 1999-01-27 | 2014-09-03 | Σχηματισμοi οι οποiοι περιλαμβανουν αντι-κωδικευσης νουκλεοτιδια σε συνδετινες |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100703T CY1115521T1 (el) | 1999-01-27 | 2014-09-03 | Σχηματισμοi οι οποiοι περιλαμβανουν αντι-κωδικευσης νουκλεοτιδια σε συνδετινες |
Country Status (13)
| Country | Link |
|---|---|
| US (11) | US7098190B1 (enExample) |
| EP (3) | EP1621212B1 (enExample) |
| JP (4) | JP4994533B2 (enExample) |
| AT (2) | ATE300959T1 (enExample) |
| AU (1) | AU776512B2 (enExample) |
| CA (2) | CA2730386C (enExample) |
| CY (2) | CY1112557T1 (enExample) |
| DE (1) | DE60021700T2 (enExample) |
| DK (3) | DK1621212T3 (enExample) |
| ES (3) | ES2377749T3 (enExample) |
| NZ (1) | NZ513154A (enExample) |
| PT (3) | PT1146908E (enExample) |
| WO (1) | WO2000044409A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5991308A (ja) * | 1982-11-16 | 1984-05-26 | Kawasaki Heavy Ind Ltd | 平面の検出方法 |
| PT1146908E (pt) * | 1999-01-27 | 2005-10-31 | David Dr Becker | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
| EP1197553A1 (en) * | 2000-10-12 | 2002-04-17 | A3D GmbH, Antisense Design & Drug Development | Antisense nucleic acid against alphaV integrin |
| US20050119211A1 (en) * | 2001-05-18 | 2005-06-02 | Sirna Therapeutics, Inc. | RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA) |
| DK1699924T3 (da) | 2003-12-03 | 2019-10-21 | Ocunexus Therapeutics Inc | Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume |
| US9408381B2 (en) | 2004-12-21 | 2016-08-09 | Musc Foundation For Research Development | Alpha Connexin c-Terminal (ACT) peptides for use in transplant |
| JP5243040B2 (ja) | 2004-12-21 | 2013-07-24 | ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント | 創傷治癒および組織再生を促進するための組成物および方法 |
| ES2766549T3 (es) | 2005-02-03 | 2020-06-12 | Coda Therapeutics Ltd | Compuestos anticonexina 43 para el tratamiento de heridas crónicas |
| JPWO2007055224A1 (ja) * | 2005-11-08 | 2009-04-30 | 関西ティー・エル・オー株式会社 | 角膜疾患治療剤 |
| JP5713377B2 (ja) | 2005-12-28 | 2015-05-07 | ザ スクリプス リサーチ インスティテュート | 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物 |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| JP5960944B2 (ja) * | 2006-11-15 | 2016-08-02 | コーダ セラピューティクス， インコーポレイテッド | 創傷治癒のための改善された方法および組成物 |
| AU2014204482B2 (en) * | 2006-12-11 | 2016-07-07 | Coda Therapeutics, Inc. | Anticonnexin polynucleotides as impaired wound healing compositions |
| US8063023B2 (en) * | 2006-12-11 | 2011-11-22 | Coda Therapeuctics, Inc. | Impaired wound healing compositions and treatments |
| JP5552048B2 (ja) * | 2007-06-21 | 2014-07-16 | ムスク ファンデーション フォー リサーチ ディベロップメント | 加齢性黄斑変性を治療するためのアルファコネキシンｃ末端（ａｃｔ）ペプチド |
| WO2009044392A2 (en) | 2007-10-03 | 2009-04-09 | Quark Pharmaceuticals, Inc. | Novel sirna structures |
| AU2008335717A1 (en) | 2007-12-11 | 2009-06-18 | Coda Therapeutics, Inc. | Impaired wound healing compositions and treatments |
| JP2011506447A (ja) * | 2007-12-11 | 2011-03-03 | コーダ セラピューティクス， インコーポレイテッド | 損傷した創傷治癒組成物および治療 |
| AU2008343841A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
| JP2011507858A (ja) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス， インコーポレイテッド | 整形外科状態の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた、抗コネキシンペプチドの使用 |
| WO2009085275A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions |
| EP2252690A2 (en) * | 2007-12-21 | 2010-11-24 | Coda Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars |
| WO2009085273A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
| EP2238250B1 (en) * | 2007-12-21 | 2017-07-19 | CoDa Therapeutics, Inc. | Use of anti-connexin 43 polynucleotides, peptides or antibodies for the treatment of orthopedic conditions |
| CA2710223A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of surgical adhesions |
| WO2009085272A2 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Improved medical devices |
| CA2710232A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of abnormal or excessive scars |
| WO2009097077A2 (en) * | 2008-01-07 | 2009-08-06 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
| ES2727549T3 (es) | 2008-10-03 | 2019-10-17 | Curna Inc | Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1 |
| CA2745811C (en) | 2008-12-04 | 2021-07-13 | Joseph Collard | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene |
| WO2010065671A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
| JP6091752B2 (ja) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Ｅｐｏに対する天然アンチセンス転写物の抑制によるエリスロポエチン（ｅｐｏ）関連疾患の治療 |
| US8669941B2 (en) * | 2009-01-05 | 2014-03-11 | Nuance Communications, Inc. | Method and apparatus for text entry |
| KR101682735B1 (ko) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료 |
| MX2011009751A (es) | 2009-03-16 | 2011-09-29 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. |
| JP5904935B2 (ja) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | デルタ様１ホモログ（ｄｌｋ１）に対する天然アンチセンス転写物の抑制によるｄｌｋ１関連疾患の治療 |
| EP2427552B1 (en) | 2009-05-06 | 2016-11-16 | CuRNA, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
| WO2010129799A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| CA2761248C (en) | 2009-05-08 | 2023-03-14 | Joseph Collard | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
| EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
| CA2762987A1 (en) | 2009-05-22 | 2010-11-25 | Joseph Collard | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
| ES2618576T3 (es) | 2009-05-28 | 2017-06-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico |
| ES2629339T3 (es) | 2009-06-16 | 2017-08-08 | Curna, Inc. | Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1 |
| EP2443237B1 (en) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
| JP6073133B2 (ja) | 2009-06-24 | 2017-02-01 | クルナ・インコーポレーテッド | 腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療 |
| CN102482672B (zh) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | 通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病 |
| JP2013500017A (ja) | 2009-07-24 | 2013-01-07 | カッパーアールエヌエー，インコーポレイテッド | サ−チュイン（ｓｉｒｔ）への天然アンチセンス転写物の阻止によるサ−チュイン（ｓｉｒｔ）関連疾患の治療 |
| KR101802536B1 (ko) | 2009-08-05 | 2017-11-28 | 큐알엔에이, 인크. | 인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료 |
| ES2599986T3 (es) | 2009-08-11 | 2017-02-06 | Curna, Inc. | Tratamiento de enfermedades relacionadas con adiponectina (ADIPOQ) mediante la inhibición de un transcrito antisentido natural de una adiponectina (ADIPOQ) |
| EP2982755B1 (en) | 2009-08-21 | 2020-10-07 | CuRNA, Inc. | Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip |
| WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
| DK2480669T3 (en) | 2009-09-25 | 2018-02-12 | Curna Inc | TREATMENT OF FILAGGRIN- (FLG) RELATED DISEASES BY MODULATING FLG EXPRESSION AND ACTIVITY |
| NO2513310T3 (enExample) | 2009-12-16 | 2018-03-31 | ||
| US9068183B2 (en) | 2009-12-23 | 2015-06-30 | Curna, Inc. | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 |
| US8940708B2 (en) | 2009-12-23 | 2015-01-27 | Curna, Inc. | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
| ES2585829T3 (es) | 2009-12-29 | 2016-10-10 | Curna, Inc. | Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63 |
| US8921334B2 (en) | 2009-12-29 | 2014-12-30 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1 |
| EP2519632B1 (en) | 2009-12-31 | 2018-04-11 | CuRNA, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
| ES2664605T3 (es) | 2010-01-04 | 2018-04-20 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8 |
| US8912157B2 (en) | 2010-01-06 | 2014-12-16 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
| NO2524039T3 (enExample) | 2010-01-11 | 2018-04-28 | ||
| US8946182B2 (en) | 2010-01-25 | 2015-02-03 | Curna, Inc. | Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1 |
| CA2790506A1 (en) | 2010-02-22 | 2011-08-25 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
| AU2011232365A1 (en) | 2010-03-24 | 2012-10-25 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| KR101877065B1 (ko) | 2010-04-02 | 2018-07-10 | 큐알엔에이, 인크. | 집락 자극 인자 3 (ｃｓｆ3)에 대한 자연 안티센스 전사체의 저해에 의한 집락 자극 인자 3 (ｃｓｆ3) 관련된 질환의 치료 |
| CN102858979B (zh) | 2010-04-09 | 2018-01-26 | 库尔纳公司 | 通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病 |
| CN107988228B (zh) | 2010-05-03 | 2022-01-25 | 库尔纳公司 | 通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病 |
| TWI531370B (zh) | 2010-05-14 | 2016-05-01 | 可娜公司 | 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病 |
| JP5973996B2 (ja) | 2010-05-26 | 2016-08-23 | カッパーアールエヌエー，インコーポレイテッド | Ａｔｏｈ１に対する天然アンチセンス転写物の阻害による無調ホモログ１（ａｔｏｈ１）関連疾患の治療 |
| EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
| DK2585596T3 (da) | 2010-06-23 | 2021-04-06 | Curna Inc | Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna |
| NO2593547T3 (enExample) | 2010-07-14 | 2018-04-14 | ||
| WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
| CA2815212A1 (en) | 2010-10-22 | 2012-04-26 | Curna, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
| US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
| CN103459599B (zh) | 2010-11-23 | 2017-06-16 | 库尔纳公司 | 通过抑制nanog的天然反义转录物而治疗nanog相关疾病 |
| JP6188686B2 (ja) | 2011-06-09 | 2017-08-30 | カッパーアールエヌエー，インコーポレイテッド | フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療 |
| BR112014005234A2 (pt) | 2011-09-06 | 2017-04-11 | Curna Inc | tratamento de doenças relacionadas com subunididades alfa dos canais de sódio dependentes de voltagem (scnxa) com pequenas moléculas |
| CA2864606C (en) | 2012-02-15 | 2021-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of treating and preventing diseases and disorders of the central nervous system |
| CA2866115C (en) | 2012-03-01 | 2020-03-24 | Firststring Research, Inc. | Topical gels containing alpha connexin c-terminal (act) peptides |
| ES2694592T3 (es) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
| US20140274872A1 (en) * | 2013-03-15 | 2014-09-18 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
| CA2868534A1 (en) | 2012-03-27 | 2013-10-03 | Coda Therapeutics, Inc. | Compositions and treatments based on cadherin modulation |
| BR112015022701A2 (pt) * | 2013-03-11 | 2018-09-25 | Univ North Carolina Chapel Hill | composições e métodos para segmentação de n-acetilglicosamina transferase o-ligada e promoção da cicatrização de feridas. |
| US9156896B2 (en) | 2013-03-15 | 2015-10-13 | Coda Therapeutics, Inc. | Wound healing compositions and treatments |
| CA2932753A1 (en) * | 2013-12-04 | 2015-06-11 | Rxi Pharmaceuticals Corporation | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| CA2940648A1 (en) * | 2014-02-25 | 2015-09-03 | Coda Therapeutics, Inc. | Treatment of resistant lesions |
| WO2015191795A1 (en) * | 2014-06-12 | 2015-12-17 | The Research Foundation For The State University Of New York | Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina |
| CA2958879A1 (en) | 2014-08-22 | 2016-02-25 | Auckland Uniservices Limited | Channel modulators |
| EP3188799B1 (en) | 2014-09-05 | 2022-07-06 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1 |
| JP7098527B2 (ja) * | 2016-02-26 | 2022-07-11 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | コネキシン（Ｃｘ）４３ヘミチャネル結合抗体及びその使用 |
| CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
| EP3685824A1 (en) | 2019-01-25 | 2020-07-29 | Breitenbronn-Consulting GbR | Composition for administering and releasing oligonucleotides |
| JP2023546757A (ja) | 2020-10-22 | 2023-11-07 | シークエル・バイオ・インコーポレイテッド | ペプチド製剤および眼科におけるその使用 |
| EP4522638A1 (en) * | 2022-05-13 | 2025-03-19 | University of Utah Research Foundation | Gja1-20k to limited cardiac arrhythmias |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425930D0 (en) | 1994-12-22 | 1995-02-22 | Procter & Gamble | Silicone compositions |
| JP2000504670A (ja) * | 1996-01-31 | 2000-04-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 腫瘍細胞の成長を抑制する方法 |
| EP1464704B1 (en) * | 1996-03-07 | 2006-10-11 | Eisai Co., Ltd. | Mouse adhesion molecule occludin |
| WO1998002150A1 (en) * | 1996-07-17 | 1998-01-22 | Medtronic, Inc. | System for genetically treating cardiac conduction disturbances |
| EP0950060A4 (en) * | 1996-12-02 | 2000-07-05 | Dyad Pharmaceutical Corp | COUNTERSTRAIN INHIBITION OF HUMAN ADHESION MOLECULES |
| EP1037981A1 (en) * | 1997-12-09 | 2000-09-27 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
| PT1146908E (pt) * | 1999-01-27 | 2005-10-31 | David Dr Becker | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
-
2000
- 2000-01-27 PT PT00901236T patent/PT1146908E/pt unknown
- 2000-01-27 AT AT00901236T patent/ATE300959T1/de active
- 2000-01-27 PT PT100131804T patent/PT2314321E/pt unknown
- 2000-01-27 US US09/890,363 patent/US7098190B1/en not_active Expired - Lifetime
- 2000-01-27 CA CA2730386A patent/CA2730386C/en not_active Expired - Fee Related
- 2000-01-27 DE DE60021700T patent/DE60021700T2/de not_active Expired - Lifetime
- 2000-01-27 AU AU21193/00A patent/AU776512B2/en not_active Ceased
- 2000-01-27 AT AT05016736T patent/ATE533515T1/de active
- 2000-01-27 DK DK05016736.0T patent/DK1621212T3/da active
- 2000-01-27 ES ES05016736T patent/ES2377749T3/es not_active Expired - Lifetime
- 2000-01-27 EP EP05016736A patent/EP1621212B1/en not_active Expired - Lifetime
- 2000-01-27 ES ES00901236T patent/ES2245638T3/es not_active Expired - Lifetime
- 2000-01-27 WO PCT/GB2000/000238 patent/WO2000044409A1/en not_active Ceased
- 2000-01-27 ES ES10013180.4T patent/ES2498745T3/es not_active Expired - Lifetime
- 2000-01-27 NZ NZ513154A patent/NZ513154A/xx not_active IP Right Cessation
- 2000-01-27 PT PT05016736T patent/PT1621212E/pt unknown
- 2000-01-27 DK DK10013180.4T patent/DK2314321T3/da active
- 2000-01-27 JP JP2000595711A patent/JP4994533B2/ja not_active Expired - Lifetime
- 2000-01-27 EP EP10013180.4A patent/EP2314321B1/en not_active Expired - Lifetime
- 2000-01-27 DK DK00901236T patent/DK1146908T3/da active
- 2000-01-27 EP EP00901236A patent/EP1146908B1/en not_active Expired - Lifetime
- 2000-01-27 CA CA2361251A patent/CA2361251C/en not_active Expired - Fee Related
-
2006
- 2006-06-05 US US11/447,599 patent/US20070037765A1/en not_active Abandoned
- 2006-08-25 US US11/510,280 patent/US7615540B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,498 patent/US7879811B2/en not_active Expired - Fee Related
- 2006-08-25 US US11/510,496 patent/US7919474B2/en not_active Expired - Fee Related
- 2006-08-29 US US11/512,730 patent/US20070072819A1/en not_active Abandoned
- 2006-08-29 US US11/512,735 patent/US7902164B2/en not_active Expired - Fee Related
- 2006-08-29 US US11/512,728 patent/US20070066555A1/en not_active Abandoned
- 2006-08-29 US US11/512,725 patent/US20080249041A1/en not_active Abandoned
-
2009
- 2009-11-30 US US12/592,668 patent/US8314074B2/en not_active Expired - Fee Related
-
2011
- 2011-08-19 JP JP2011179832A patent/JP2012041342A/ja active Pending
-
2012
- 2012-02-09 CY CY20121100139T patent/CY1112557T1/el unknown
- 2012-11-19 US US13/681,383 patent/US9193754B2/en not_active Expired - Fee Related
-
2013
- 2013-01-30 JP JP2013015171A patent/JP5705890B2/ja not_active Expired - Lifetime
- 2013-01-30 JP JP2013015172A patent/JP5736397B2/ja not_active Expired - Lifetime
-
2014
- 2014-09-03 CY CY20141100703T patent/CY1115521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112557T1 (el) | Σχηματισμoi οι οποiοι περιλαμβανουν αντι-κωδικεyσης νουκλεοτιδια σε συνδετινες | |
| ES2071484T3 (es) | Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral. | |
| FR2759581B1 (fr) | Dispositif de traitement, notamment par moxa, de type acupressure | |
| MX9801596A (es) | Composiciones aliviadoras del prurito, cosmeticas y farmaceuticas o ambas. | |
| PT1235571E (pt) | Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino | |
| PT971694E (pt) | Preparacoes de medicamentos para o tratamento de disfuncao sexual | |
| NO20002972L (no) | N-benzyl-3-indenylacetamidderivater for behandling av neoplasi | |
| TR200001040T2 (tr) | Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı | |
| TR200201071T2 (tr) | Rar selektif retinoid antagonistleri kullanılarak anfizem tedavisi | |
| ITMI992107A0 (it) | Uso del baclofen nel trattamento dell'astinenza da etanolo | |
| TR199801452T2 (xx) | Jinekolojik rahats�zl�klar�n tedavisinde kullan�lan LHRH analoglar� ve anti�strojenlerden m�te�ekkil farmakolojik kombine madde. | |
| ITRM970731A0 (it) | Composizione per il trattamento di ustioni eritemi solari abrasioni piaghe e irritazioni cutanee | |
| ES2068714T3 (es) | Derivados de pirimidina para aumentar la actividad antitumoral. | |
| BR0014372A (pt) | Derivados de 5-hidroxissapogenina com atividade antidemência | |
| NO970178L (no) | Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler | |
| DE59002772D1 (de) | Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms. | |
| EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
| ES2144857T3 (es) | Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso. | |
| IT8619457A0 (it) | Derivati insaturi cicloalifatici, loro procedimenti di prepatazione e loro impiego in terapia e in cosmetica. | |
| PT1011649E (pt) | Utilizacao de endipaleno no tratamento de psoriase | |
| DK72188A (da) | Saarbehandlingsmiddel og kosmetisk middel | |
| DE69825307D1 (de) | Verwendung von protein h als zytostattischer wirkstoff | |
| UA29165A (uk) | Світлолікувальний пристрій | |
| TR199800705T2 (enExample) | ||
| IT1280629B1 (it) | Tripeptide per il trattamento delle forme cancerose, in particolare per il trattamento del melanoma. |